NCT03676257 2025-12-10
Survival Endpoints in Women Treated for Metastatic Breast Cancer: Contribution of Real-life Databases
Institut Bergonié
Completed
Clinical Trials
12 trialsNCT02000596 2022-05-27
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.
University of Maryland, Baltimore
Phase 2 Terminated
NCT01712009 2018-01-30
NOLAN
Amgen
Phase 2 Completed
NCT00382018 2017-11-06
S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo
SWOG Cancer Research Network
Phase 3 Completed
NCT00074152 2017-06-16
CALOR
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT01298362 2016-09-20
POCHARBI
Hellenic Breast Surgeons Society
Completed
NCT01368263 2015-04-03
Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer
Washington University School of Medicine
Phase 2 Terminated
NCT00448279 2014-10-24
THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
Hoffmann-La Roche
Phase 3 Completed
NCT01928615 2014-09-29
LISAH
Hoffmann-La Roche
Phase 2 Terminated
NCT02115984 2014-07-15
Study of the Safety and Leukostimulatory Activity of the Preparation "Panagen" in Patients With Breast Cancer
Panagen, Limited Liability Company
Phase 2 Completed
NCT00262067 2013-12-13
A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)
Genentech, Inc.
Phase 3 Unknown
NCT00246571 2012-07-12
Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer
Pfizer
Phase 2 Completed